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Background: Solitary fibrous tumors of the pleura (SFTP) refer as 
to a heterogeneous group of mesenchymal malignancies with vari-
ous anatomic and histology features. Upfront surgical resection is the 
standard approach, but recurrences may be aggressive and difficult to 
treat. The most widely accepted staging system has been proposed by 
De Perrot et al. Because SFTPs are rare, evidence to support a role 
for perioperative chemotherapy is scarce. Likewise, the predictive or 
prognostic relevance of the De Perrot system may be questioned.
Methods: Multicenter retrospective study of patients with histologi-
cally proven SFTP with complete follow-up from surgical diagnostic 
to tumor recurrence and death.
Results: Sixty-eight patients were included. Tumor stage was 0/I for 29 
(43%) patients, II for 23 (34%) patients, III for seven (10%) patients, 
and IV for nine (13%) patients. Postoperative chemotherapy was given 
to seven patients, mostly with stage III/IV SFTP, mostly consisting of 
doxorubicin-based regimen. Recurrence rate and median relapse-free 
survival after surgery were 3%, 52%, 71%, and 80% (p < 0.001), and 
107, 70, 29, 11 months (p < 0.001) for stage 0/I, II, III, and IV tumors, 
respectively. At time of tumor recurrence, 14 patients received exclu-
sive chemotherapy. Highest disease control rates were observed with 
trabectedin, and gemcitabine–dacarbazine combination.
Conclusion: Our study confirms the prognostic value of the De Perrot 
staging system, as well as its possible predictive value for perioperative 
chemotherapy decision-making, whereas the efficacy of currently avail-
able regimens to significantly reduce the risk of tumor recurrence remains 
questionable. Trabectedin may be of interest for recurrent tumors.
Key Words: Solitary fibrous tumor, Pleura, Surgery, Chemotherapy, 
Trabectedin.
(J Thorac Oncol. 2015;10: 309–315)
Solitary fibrous tumors (SFT) are rare mesenchymal malig-nancies of pluripotent fibroblastic and myofibroblastic 
origin, which may arise anywhere in the body, and may be 
aggressive and difficult to treat.1–4 Over the years, SFT of the 
pleura (SFTP) have been referred as to “localized mesothelio-
mas”, “localized fibrous tumors”, “fibrous mesothelioma”, or 
“pleural fibroma”, stressing their heterogeneity with regard to 
histology and aggressiveness, and leading to consider SFTP 
as a separate entity among other solitary fibrous tumors.2,3 
Clinically, SFTP are often diagnosed at an early stage, pre-
senting as pedunculated localized masses with benign his-
tologic features; outcome is then favorable after complete 
resection.3–8 Most of the available literature actually reports 
on this subset of patients. However, approximately 10–15% 
of SFTPs harbor an aggressive phenotype with local and sys-
temic recurrences. The criteria used to predict such malignant 
behavior have mostly been focused on histology4–10; other pre-
dictors are unknown or not consistently reported.
The most widely accepted consensus about the manage-
ment of SFTP was proposed by De Perrot et al.11 in 1999, and 
is based on a pooled analysis of the 185 cases then reported in 
the literature. A five-class scheme based on morphologic and 
histologic features was established and associated with pro-
posals for postoperative treatment and follow-up, but virtu-
ally no data have been made available to validate this strategy 
algorithm.4,11 Evidence is even more limited about the man-
agement of unresectable, metastatic or recurrent SFTP, given 
the various chemotherapy regimens used, in multiple clinical 
settings, and different treatment-intent.12–15
Here, we took advantage of a multicenter cohort of 
patients, to provide a global and longitudinal view of the 
management of SFTP, through an extensive analysis of the 
outcome of patients after surgery, focusing on recurrences, 
systemic treatment, and long-term outcome, applying the De 
Perrot system as a reference.
MATERIALS AND METHODS
Study Population
This retrospective, noninterventional study was con-
ducted within a National Cancer Institute-funded, dedicated 
Network for the Study of Rare Thoracic Neoplasms in France 
(www.orphonco-thorax.org). Four institutions participated in 
the study: Louis Pradel Hospital - National Pilot Center of the 
Network - and Leon Berard Cancer Center in Lyon, University 
Hospital of Toulouse, and Percy Military Hospital in Clamart. 
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Inclusion criteria were the following: (1) pathologically proven 
SFTP; (2) diagnosed between January 1, 2000 and December 
31, 2012; (3) available complete follow-up. Patients were 
identified using pathology and/or hospital databases.
Clinical and Pathological Review
A retrospective review of the clinical history of eligible 
patients was performed. The study was formally approved by 
the Protocol Assessment and Review Ethics Committee of 
the French National Respiratory Medicine Society. Patients 
had been treated according to each institution standards. A 
questionnaire was designed to collect clinical data, physical 
examination, results from imaging investigations (e.g., chest 
radiography and computed tomography [CT] scan; brain CT 
or magnetic resonance imaging; abdomen ultrasound or CT; 
18-fluorodeoxyglucose-positon emission tomography scan, 
and bone scintigraphy when performed), pathological reports, 
and blood tests results. Patients were categorized as never 
smokers (less than 100 lifetime cigarettes), former smokers 
(quit more than 1 year ago), or current smokers (active smok-
ers or quit less than 1 year ago).
Systematic pathological review was performed at each 
institution. Tumors were classified as benign or malignant based 
on the identification of the four standard malignancy criteria 
reported by England et al.10: (1) high mitotic activity (greater 
than 4 mitosis/10 high-power fields, i.e., magnification ×400); 
(2) high cellularity with crowding and overlapping of nuclei; (3) 
the presence of necrosis; and (4) cellular pleomorphism.
The five-stage classification proposed by De Perrot was 
assessed for all patients3,11: (1) stage 0, pedunculated tumor 
without signs of malignancy; (2) stage I, sessile or “inverted” 
tumor without signs of malignancy; (3) stage II, pedunculated 
tumor with histologic signs of malignancy; (4) stage III, ses-
sile or “inverted” tumor with histologic signs of malignancy; 
and (5) stage IV, multiple synchronous metastatic tumors.
Outcome
Tumor progression and recurrence after treatment was usu-
ally diagnosed using CT scan. Best response to chemotherapy 
was evaluated according to Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria v1.1.16 Disease control rate (DCR) 
was defined as the sum of objective response and stable disease 
rates. Relapse-free survival (RFS) and time-to-progression (TTP) 
were calculated from diagnosis to first evidence of disease pro-
gression after R0–R1 resection, or systemic treatment, respec-
tively. Overall survival was calculated from diagnosis to death.
Statistical Analyses
All patients were included in the statistical calcula-
tions. Follow-up was obtained in all cases and was censored 
on December 31, 2013. Categorical variables were compared 
using the χ2 or Student’s test where applicable, and continuous 
variables were compared using the Mann–Whitney nonpara-
metric test. Survival curves were plotted using the Kaplan–
Meier method, and compared with the log rank test. A p value 
less than 0.05 was considered significant. Statistical analyses 
were performed using the SPSS software program (Chicago, 
IL), version 17.0.
RESULTS
Study Population
A total of 68 patients were treated for SFTP at the 
participating institutions during the study period. Baseline 
characteristics of these 68 patients are presented in Table 1. 
Median age was 62 years (range, 31–85). The majority of 
patients were never smoker (72%) and in a good medical 
condition, as 96% of patients had a performance status of 
0/1. More than a half of the tumors were discovered after 
clinical symptoms occurred; the most frequent were dyspnea 
(18% of cases) and chest pain (21% of cases). Interestingly, 
six (10%) patients had paraneoplastic syndromes, includ-
ing refractory hypoglycemia in two and hypertrophic osteo-
arthropathy (7%),17 both revealing the tumor. At imaging, 
the tumor was located in the right hemithorax in 28 (41%) 
patients and in the left hemithorax in 40 (59%) patients. The 
mean time between the first symptoms or abnormal chest 
imaging for asymptomatic patients and first treatment was 
39 months (range, 0–78 months).
Diagnosis of the Tumor
Sixty-four (94%) patients underwent surgical resection 
of SFTP (Fig. 1). Surgical approaches included open thora-
cotomy in 57 (91%) cases, and video-assisted thoracoscopy 
in six (9%) cases. Macroscopically, the mean tumor size was 
90 mm (range, 28–250 mm) with a mean weight of 1110 g 
(range, 230–2200 g). Tumor was pedunculated in 48 (75%) 
patients, and sessile in 16 (25%) patients. Resection was com-
plete (R0) in 57 (89%) patients, microscopically incomplete in 
five (8%) patients; resection was macroscopically incomplete 
in two (3%) patients. Peroperative fragmentation or rupture of 
the tumor occurred in three patients.
Only four (6%) patients were not operated on. All four 
patients had metastatic disease, observed at radiological imag-
ing, and diagnosis was made on small biopsies. One patient, 
aged 79 years, had asymptomatic SFTP, and given coexisting 
altered performance status and significant comorbidities, was 
managed with best supportive care only.
Microscopically, the diagnosis of benign SFTP was made 
in 29 (43%) patients, and of malignant SFTP in 39 (57%) 
patients. Overall, tumor stage according to the De Perrot system 
was 0/I for 29 (43%) patients, II for 23 (34%) patients, III for 
seven (10%) patients, and IV for nine (13%) patients (Fig. 1). 
Tumor stage after review was consistent in all cases with that 
assessed locally.
First-Intent Chemotherapy
First-intent chemotherapy was administered either as 
perioperative, curative-intent treatment, or as a definite, pos-
sibly palliative, treatment (Figs. 1, 2).
Perioperative chemotherapy was administered to 10 
(15%) patients (Fig. 2, Table 2): three patients received peri-
operative chemotherapy, including combination of mesna, 
doxorubicin, ifosfamide, and dacarbazine in one case, and 
doxorubicin alone in two cases; in those patients, the intent of 
the treatment was to reduce the tumor burden and subsequently 
allow surgical resection; this was actually not achieved for any 
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of these patients, two of whom even presented with tumor pro-
gression during chemotherapy.
Postoperative chemotherapy was administered to 
seven (11%) patients, all with stage III/IV SFTP, and con-
sisting of doxorubicin-based regimen in six patients, for a 
total of 4–6 cycles (Fig. 2, Table 2); one patient received 
cisplatin–pemetrexed chemotherapy for a tumor initially 
thought to be non–small-cell lung cancer. Two patients 
experienced tumor progression during postoperative 
chemotherapy.
Overall, the decision-making to administer chemother-
apy was reported to be mostly based on histologic criteria: 
invasion of the resection margins (6 out of 7 patients), and/or 
the presence of England’s poor prognostic factors (6 out of 7 
patients had at least three factors of poor prognosis). No clini-
cal, surgical, or radiological features were reported to have 
been taken into account in this setting; this was in accordance 
with the De Perrot recommendations in 6 of 7 cases (85%).
Palliative chemotherapy was given to one patient who 
presented with unresectable abdominal metastases. Treatment 
consisted of six cycles of doxorubicin, leading to tumor stabi-
lization. Sequential conformal radiotherapy to a total dose of 
54 Gy was subsequently delivered.
Overall, 62 (92%) patients were treated in accordance 
with the De Perrot proposals (Fig. 1).
Chemotherapy for Recurrence
Of the 68 patients, 26 (38%) patients presented with 
SFTP recurrence after first-intent treatment. Recurrences 
occurred in the pleura in 14 (54%) patients, and at distant sites 
in 12 (46%) patients. Recurrence rates after surgery were 3%, 
52%, 71%, and 80% in patients with stage 0/I, II, III, and IV 
tumors, respectively, (p < 0.001). Median RFS was 107, 70, 
29, and 11 months (p < 0.001), respectively (Fig. 3). Besides 
tumor stage, predictors of shorter RFS were incomplete (R1 or 
R2) resection (p < 0.001), and a higher number of histologic 
signs of malignancy (p = 0.009).
Treatment of recurrence consisted of surgical reresec-
tion in 12 patients, two of whom received postoperative che-
motherapy; reresection was complete (R0) in seven (58%) 
patients, providing patients with a median RFS of 21 months. 
12 patients received definitive chemotherapy, and two with a 
poor functional status received best supportive care (Fig. 4).
Overall, chemotherapy for recurrence had a modest 
benefit with response and DCR as low as 9% and 39%, respec-
tively. Highest DCRs were observed with trabectedin (total 
nine patients; partial response: three patients; DCR: seven 
(78%) patients; median TTP: 3.4 months), and gemcitabine–
dacarbazine combination (total three patients; partial response 
rate: one patient; DCR: 66%; median TTP: 1.9 months). 
Beyond second-intent chemotherapy, 13 patients received 
subsequent lines of chemotherapy.
Median overall survival of the whole cohort was 56 months.
TABLE 1.  Patients Characteristics
n %
Total 68 100
  Sex
  Men 28 41
  Women 40 59
Age (years)
  Median 62.2
  Range 31–85
Performance status
  0 36 53
  1 29 43
  2 3 4
Clinical symptoms
  No 29 43
  Yes 39 57
   Chest pain 14 21
   Dyspnea 12 18
   Cough 5 7
   Hypoglycemia 2 3
   Osteoarthropathy 4 6
   Weight loss 5 7
   Others 4 6
Tumor location
  Right 28 41
  Left 40 59
Surgical resection
  No 4 6
  Yes 64 94
   R0 57 84
   R1 5 7
   R2 2 3
FIGURE 1.  First-intent treatment 
and recurrences according to the De 
Perrot stage. S, surgery; C, chemo-
therapy; R, radiotherapy.
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DISCUSSION
Here, we report on a large series of patients with SFTP 
analyzed for the complete course of disease in a routine prac-
tice setting, from initial surgical resection to treatment of 
advanced disease with chemotherapy. Our results highlight 
for the first time, to the best of our knowledge, the relevance 
of the De Perrot staging system beyond its prognostic value, 
i.e., with regard to the decision-making for perioperative che-
motherapy, which, however, showed very limited efficacy. Our 
data indicate that nearly half of SFTP recurrences may be eli-
gible for surgical resection, achieving complete resection and 
prolonged survival in a majority of cases; besides adriamycin-
based chemotherapy regimens, trabectedin may represent an 
option in the setting of unresectable tumors.
The staging of SFTP is mostly based on surgical speci-
mens, as surgery is usually the first step and the mainstay of 
the therapeutic strategy.8,10,18 In our series, 94% of patients 
underwent resection of the tumor. The staging system pro-
posed by De Perrot et al. relies on the anatomy of the tumor 
(sessile or pedunculated) and the presence of histologic signs 
of malignancy3; among the 185 cases that were reviewed to 
establish this classification, which mostly originated from sur-
gical series, 127 cases (69%) did not harbor any histologic 
sign of malignancy, and were then classified either as stage 
0—if pedunculated (34%), or stage I—if sessile (35%).3 No 
metastastic stage IV SFTP had been included in this analysis, 
whereas some of these may actually be eligible for surgery (5 
out of 9 cases in our series).
Excluding stage IV tumors, tumor stage was 0 for 39%, 
I for 10%, II for 39%, and III for 12% of our cases. In other 
recently reported series, the relative proportion of stages 
ranged from 67% to 86% for stage 0/I and 14% to 43% for 
stage II/III tumors, respectively.4,5,7,8,10 These discrepancies 
are not well understood, and may be related to the retrospec-
tive nature of all these analyses, and the frequent absence of 
systematic pathological review; in our series, the diagnosis of 
benign SFTP was made in 29 patients (43%), and of malig-
nant SFTP in 39 patients (57%).
FIGURE 2.  First-intent chemotherapy: intent of the 
treatment, regimen, and response. Doxo, doxoru-
bine; MAID, mesna, doxorubicine, ifosfamide, and 
dacarbazine; CDDP–PEM, cisplatine and peme-
trexed; PD, progressive disease; SD, stable disease; 
CR, complete response (indicates the absence of 
residual tumor after surgery).
TABLE 2.  Chemotherapy Treatment
Treatment/Regimen
First-linea Second-line Third-line
n DC (%) PD (%) n DC (%) PD (%) n DC (%) PD (%)
Cytotoxic agents
  MAID 6 83 17 1 0 100 0 … …
  Doxorubicine 4 25 75 4 50 50 5 20 80
  Brostacilline 0 … … 1 0 100 1 100 0
  Paclitaxel weekly 0 … … 2 0 100 1 0 100
  Gemcitabine weekly 0 … … 0 … … 5 0 100
  Gemcitabine/Dacarbazine 0 … … 0 … … 3 66 33
  Vinorelbine 0 … … 0 … … 2 0 100
  Docetaxel 0 … … 1 100 0 2 0 100
  Cisplatin–pemetrexed 1 100 0 … … … … … …
  Trabectedin 0 … … 1 100 0 8 75 25
Antiangiogenic treatment
  Pazopanib 0 … … 3 0 100 1 0 100
  Sunitinib 0 … … 1 0 100 2 0 100
aIncluding perioperative treatment.
MAID: mesna, doxorubine, ifosfamide, dacarbazine, DC: disease control, PD: progressive disease.
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Our follow-up data compare well, except for stage II, with 
that of the De Perrot series, with regard to recurrence rates (3% 
versus 5% in stage 0/I, 52% versus 14% in stage II, 71% ver-
sus 63% in stage III).3 Furthermore, although limited survival 
analysis is available from previous reports, possibly because of 
limited follow-up, our results validate De Perrot staging system 
as a major prognostic factor, as median RFS, which represent 
a better outcome than overall survival given the low number 
of SFTP-related events in benign tumors, was 107, 70, 29, and 
11 months (p = 0.006), in stage 0/I, II, III, and IV, respectively 
(Fig. 3). These data highlight the major weight of histologic fea-
tures in the outcome, whereas the anatomic pattern, i.e., sessile 
or pedunculated implantation, may be overweighed by com-
pleteness of resection, a major predictive factor in our series 
(p < 0.001) and others,4,5,10 which may not be significant at 
multivariate analysis when focusing on malignant SFTP.9 In the 
De Perrot series, histologic signs of malignancy were more fre-
quently present in case of sessile implantation (stage III cases) 
than in case of pedunculated implantation (stage II; 23% ver-
sus 8% of cases, respectively). This was also suggested in other 
series, with 75% of benign TFSP being pedunculated, and 69% 
of malignant TFSP presenting with sessile implantation.4
Beyond anatomic features, the TTP difference between 
stage II and III disease remains of major clinical relevance; 
this may be related to an increasing cellular aggressiveness, 
as suggested by the unfavorable prognostic value of a higher 
number of histologic signs of malignancy in the tumor, identi-
fied in our series and others.9 Long-term follow-up of patients 
with SFTP, even classified as stage II, would then be recom-
mended to detect recurrences; half yearly follow-up would 
be proposed for the first 3 years, when the majority of recur-
rences occurred in our series.
Our results highlight for the first time, to the best of our 
knowledge, the value of the De Perrot staging system beyond 
its prognostic value. In a landmark article, De Perrot et al. 
recommended, based on their literature review, to administer 
adjuvant chemotherapy exclusively for stage III—i.e., sessile 
malignant—SFTP.3 Whereas no study validated this strategy, 
62 patients (92%) in our series were treated in accordance 
with the De Perrot proposals. Available data are limited in the 
literature with regard to the role of perioperative chemother-
apy in SFTP, given the low number and the heterogeneity of 
reported cases with regard to treatment regimen, tumor stage, 
setting, and intent of the treatment. Biologically, the role 
of chemotherapy is often criticized given the reported low-
mitotic rate and the low cellularity; whereas this is the case 
in stage I tumors, II, III, and IV SFTP actually present with 
florid cellularity and systemic aggressiveness.10 Moreover, 
contrary to SFT occurring in other anatomic location, such as 
soft tissues, for which postoperative chemotherapy is rarely 
considered and radiotherapy represent an option in R1/R2 dis-
ease, the role of postoperative treatment has been considered 
to be major in SFTP given the higher risk of microscopically 
incomplete resection.4–10
In our series, chemotherapy was administered after sur-
gery for stage III/IV SFTP, and mostly consisted of doxorubi-
cin-based regimen, with limited efficacy as the vast majority of 
patients ultimately experienced tumor recurrence. The fact that 
two patients experienced progression during adriamycin-based 
postoperative chemotherapy highlights the aggressiveness of 
the disease. Overall, the systematic delivery of postoperative 
chemotherapy is, based on our data, questionable.
With regard to stage II disease, our data indicate a 52% 
recurrence rate, contrasting with a TTP as high as 70 months, 
suggesting that heterogeneity exists, with possible indolent 
course, frequent eligibility to reresection, and some response 
to chemotherapy at time of recurrence. A subset of stage II 
patients would then theoretically benefit from postoperative 
treatment, provided more efficient regimens are being made 
available. Finally, our data suggest the poor value of preop-
erative chemotherapy aiming at reducing the tumor burden of 
stage IV unresectable tumors, to subsequently allow resection, 
as all patients experienced progression during treatment.
The management of unresectable TFSP remains a major 
challenge; in our series, as many as 33% patients received che-
motherapy as the sole treatment modality at some point of the 
disease history. The proportion of patients not eligible for rere-
section actually increases from first (6% of cases) to second and 
third-line treatment (46% of cases). In this setting, SFTP, given 
its rarity and the absence of dedicated study, has usually been 
FIGURE 3.  Relapse-free survival after first-intent surgery, 
according to the De Perrot stage.
FIGURE 4.  Treatment of first recurrence. Post-op CT, post-
operative chemotherapy; CT, chemotherapy.
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regarded as a subset of soft-tissue sarcomas, and chemotherapy 
regimens are again mostly based on anthracyclins19: in our series, 
23% of patients received such regimen as an exclusive treatment 
at some point of the management of their disease. Beyond first-
line treatment, our data indicate the absence of consensual strat-
egy, as 12 different regimens were reported to be administered. 
Overall, most of chemotherapy regimens used in our series had 
a modest benefit with a DCR of 38%. Similar DCR of 43% was 
reported in a recent series of 31 SFT, 10 of which were of pleu-
ral origin, receiving anthracyclin-based chemotherapy.13 These 
figures may be lower than what was observed in SFT overall, for 
which DCR ranging from 66% to 89% were reported.12,20 In our 
series, trabectedin produced the highest DCR (78%) observed in 
the nine patients treated, for a median TTP of 3.4 months, what is 
in line with figures reported in other soft-tissue malignancies.21 
One case of recurrent SFTP treated with trabectedin was previ-
ously reported, with a TTP as high as 8 months.22
Overall, these results further highlights the need for a bet-
ter understanding of the disease, as well as the need for new ther-
apeutic options. Antiangiogenic agent bevacizumab combined 
with temozolomide was reported to produce a 79% response 
rate, with a 9.7 months progression-free survival, in a cohort 
of SFT treated with various intents and settings.23 Multikinase 
inhibitors were reported to produce objective responses in cases 
of SFT including STFP, including imatinib,24 sunitinib,15,25 
sorafenib,15 and pazopanib.26 Biologically, the activity of ima-
tinib was reported to be associated with high expression levels of 
platelet-derived growth factor (PDGFR) by cancer cells24; ima-
tinib exposure of primary cell lines derived from SFTP led to a 
decrease of PDGFR expression and cell proliferation.27 The role 
of the PDGFR pathway in the carcinogenesis of TFSP was also 
highlighted by the identification of missense D850V mutation 
in exon 18 of the PDGFR gene in sarcoma cells derived from a 
patient presenting with sarcomatous transformation of SFTP.28
As suggested clinically by the occurrence of paraneo-
plastic refractory hypoglycemia related to insulin-like growth 
factor (IGF)-2 secretion by the tumor, the IGF receptor signal-
ing pathway is thought to be activated in the vast majority of 
SFTs; IGF1 receptor was reported to be expressed in more 
than 80% of cases,29 and may be targeted by specific monoclo-
nal antibody such as figitimumab.25
Ultimately, further molecular characterization may help to 
identify new theragnostic biomarkers. Recent whole-genome and 
transcriptome sequencing of SFTs led to the identification of a 
gene fusion of the transcriptional repressor of mitogenic pathways 
nerve growth factor inducible-A binding (NAB2) with the tran-
scriptional activator signal transducer and activator of transcrip-
tion 6 (STAT6) that was demonstrated to be oncogenic in vitro.30,31 
The gene fusion was observed in 80% of SFTs subsequently tested 
by reverse transcription polymerase chain reaction, with specific 
variant NAB2ex4-STAT6ex2/3 for pleural locations.31
To conclude, our study (1) confirms the prognostic value 
of the De Perrot staging system, as well as (2) its possible pre-
dictive value for perioperative chemotherapy decision-making, 
whereas the efficacy of currently available regimens to signifi-
cantly reduce the risk of tumor recurrence remains question-
able. Trabectedin may be of interest in the setting of recurrent 
tumors. Besides clinical data, further molecular characterization, 
including recently identified specific gene fusions, may help to 
better predict the outcome of patients with SFTP.
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